Life Science News

Wellteq Digital Health Inc. Launches North America Growth Division

Wellteq Digital Health Inc. Launches North America Growth Division

  • wellteq has appointed Mr Andrew Hvzid as Head of Growth, North America.
  • Based out of Toronto, Canada, Andrew Hvzid will be instrumental in accelerating wellteq's market share within the Corporate Wellness, Insurance and Health Provider sectors of Canada and North America, as well as leveraging the Company's existing distribution partners WTW (NASDAQ: WTW) and Garmin (NASDAQ: GRMN) in these new territories.
  • Mr Hvzid brings over a decade of executive experience in building strategic partnerships, identifying revenue-generating opportunities and optimising resources to propel growth across the health, fitness and education sectors.
  • Digital health is projected to be a USD 295.4 billion industry by 2028 with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028.
  • In 2020, North America accounted for the largest market share of the digital health industry at 38.77% and is expected to experience a steady CAGR over the forecast period.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or "wellteq"), is pleased to announce its strategic expansion into North America through the appointment of Mr. Andrew Hvizd as Head of Growth (NA) for the region. The Company recognises the importance of acquiring, developing and retaining top talent to drive commercial growth in the diverse and localised areas of the global digital health market - an industry that is projected to be valued at USD 295.4 billion by 2028[1].

As Head of Growth (NA), Andrew Hvizd will lead wellteq's go-to-market strategy in Canada and North America, enabling the Company's continued market expansion in the region. He will be instrumental in acquiring strategic partnerships and accelerating sustainable revenue growth, as well as leveraging wellteq's existing distribution partners, including WTW (NASDAQ: WTW) and Garmin (NASDAQ: GRMN), in these new territories.

"I'm excited to drive wellteq's expansion into Canada and North America by leveraging my executive experience in building strategic partnerships, identifying revenue-generating opportunities and optimising resources to propel growth across the health, fitness and education sectors," said Mr Hvizd. "We will pursue partnerships in the private and public markets to increase wellteq's distribution channels and launch innovative, first-to-market program offerings that extend the continuum of care into clinical solutions and remote patient monitoring.

"As I join the digital health space, the industry is poised to deliver meaningful and scalable health outcomes through accessible health and wellness programming based on when and how users want to consume it."

wellteq Chief Growth Officer, Olly Bridge added, "we are thrilled to have secured Andy as our Head of Growth (NA), he has a proven track record of delivering outstanding results and is that perfect blend of skills and personality fit with wellteq. The market is crying out for the kind of support that the wellteq platform provides and having someone like Andrew take it to market is going to be sensational."

The global digital health market is expected to experience a compound annual growth (CAGR) rate of 15.1% from 2021 to 2028. North America accounted for the largest market share of the industry at 38.77% in 2020 and is projected to expand at a steady compound annual growth (CAGR) rate over the forecast period.

wellteq Chief Executive Officer, Scott Montgomery said, "wellteq has been designed to expand its B2B digital health services from APAC to become global, and within its inception sector of Corporate Wellness through to Virtual Care. The strategic plan is simple and has remained unchanged for years, its equal parts gratifying and exciting to see this plan unfold by expanding into North America, the most mature digital health market on the planet.

"I'm delighted wellteq can attract talent with the calibre of Andrew, and already impressed with how he's activated his network with our proposition. I have no doubt wellteq's North American business will grow strongly under his and Olly's leadership."

References

1. Digital Health Market Size, Share & Trends Analysis Report by Technology (Healthcare Analytics, mHealth), By Component (Software, Services), By Region, And Segment Forecasts, 2021 - 2028.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading global provider of personalized digital health and wellness solutions across the continuum of care. To learn more, visit https://wellteq.co/.

Download the wellteq Corporate Presentation:

https://wellteq.co/about/investors/

wellteq Investor Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/118742

News Provided by Newsfile via QuoteMedia

WTEQ:CC
wellteq Digital Health Inc. Announces Health Insurer Partner Extends the wellteq Digital Health Solution to All Australians

wellteq Digital Health Inc. Announces Health Insurer Partner Extends the wellteq Digital Health Solution to All Australians

  • nib (ASX: NHF) extends wellteq's digital health solutions to all Australians through the launch of GreenPass.

  • wellteq's digital health solution integrates its preferred partners, including Garmin (NASDAQ: GRMN) and other health provider partners, into the nib-customised digital wellness app to deliver several benefit pathways, from online health assessments, personalised content and rewards to expanding virtual care services.
  • Digital health is projected to be a USD 295.4 billion industry by 2028 with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028.
  • Asia-Pacific (APAC) is expected to register the fastest CAGR over the forecast period due to the rising usage of tablets, smartphones, and other mobile platforms across the region, which includes Australia, Japan, China, India, South Korea and Singapore.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or "wellteq"), is pleased to announce that one of Australia's largest health insurers, nib holdings limited (ASX: NHF), will now offer wellteq's digital health solution to all Australians, a population of over 25 million people.

nib Group (nib) is a trusted international health partner with over one million members across Australia. The launch of nib's GreenPass membership provides Australians with access to a range of exclusive health and wellness benefits without the need to take out a traditional health insurance product. The subscription-based service aims to empower more people to put their health and wellbeing first. Read more from nib's press release:

https://www.nib.com.au/media/2022/04/media-pages-nib-launches-unique-greenpass-health-membership

wellteq's digital health solution integrates its partners, including Garmin, Fitbit, Apple, and other health provider partners, into the nib-customised digital wellness app to help them deliver personalised content and healthy action nudges, gamification, rewards and more. nib's GreenPass membership enables non-private health insurance members to access several different benefit pathways, from personalised health plans, discounts on health and wellness services, rewards for reaching health goals through their well with nib app, an online skin check, fitness tracking and exclusive pricing with nib's network of trusted health professionals.

wellteq Chief Operating Officer, Jeames Gillett said: "wellteq has been working closely with nib for several years to evolve our shared ambition of providing personalised health and wellbeing at scale. We're incredibly excited to support nib in the launch of GreenPass as it extends access beyond private health insurance members to the wider Australian population. At a time when our health and wellbeing has been tested, access to GreenPass will provide individuals with an opportunity to have personalised support on their journey to better health."

Ed Close, nib Chief Executive Australian Residents Health Insurance said: "the GreenPass is a game-changer for the industry, designed to help more Aussies access the right tools, services and information they need to support their better health."

"By making membership as much about supporting good health as the treatment of sickness and injury we have an opportunity to play a bigger role in how we help more Australians to keep healthy and out of hospital,"

"With this in mind, we created nib GreenPass, which is intentionally created to empower people of all ages to better understand their health profile and offer health and wellness perks and services they can use every day to keep on top of their health."

This timely solution aligns with market projections1 that the global digital health industry will reach USD 295.4 billion by 2028, with a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028. Asia-Pacific (APAC) is expected to register the fastest CAGR over the forecast period due to the rising usage of tablets, smartphones, and other mobile platforms across the region, which includes Australia, Japan, China, India, South Korea and Singapore.

Scott Montgomery, wellteq's Chief Executive Officer said: "when two companies missions align the synergies can create powerful things. nib's payer to partner strategy dovetails perfectly with wellteq's mission to coach healthier habits across the full continuum of healthcare. The manifestation of this synergy is GreenPass, a fantastic opportunity for anyone to try digital health tools at no cost and hopefully inspire them on a behaviour change journey that's good for them, good for nib and good for wellteq. The ideal win-win situation and another step towards proactive, equitable virtual care."

References

1. Digital Health Market Size, Share & Trends Analysis Report by Technology (Healthcare Analytics, mHealth), By Component (Software, Services), By Region, And Segment Forecasts, 2021 - 2028.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading global provider of personalized digital health and wellness solutions across the continuum of care. To learn more, visit https://wellteq.co/

Download the wellteq Corporate Presentation:

https://wellteq.co/about/investors/

wellteq Investor Contact:
Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Digital Health Inc. Announces Release of the IoMT HealthHub

Wellteq Digital Health Inc. Announces Release of the IoMT HealthHub

  • WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has released the Company's internet of medical things (IoMT) HealthHub into device integrations with Beta research partners for testing purposes.
  • The wellteq HealthHub is the result of an extensive internal development effort to produce an open standard and scalable IoMT platform for distributed virtual care deployments in enterprise health, clinic, pharmacy, and remote locations.
  • The wellteq HealthHub connects, manages, and monitors both standardized medical and non-medical devices for a completely integrated IoMT/IoT intelligent edge solution, allowing for control of any standardized commercial, industrial, residential, or medical smart device - an industry first and must-have for next generation virtual care deployments.
  • The initial market for the wellteq HealthHub will be B2B for both in-market and new-to-market virtual care solutions.
  • wellteq will soon offer its baseline B2B virtual care platform integrating the wellteq HealthHub, wellteq Clinical Vitals Wearable and the wellteq Virtual Care Coaching APP.
  • The IoMT market is projected to grow from $30.79 billion in 2021 to $187.60 billion in 2028 at a compound annual growth rate (CAGR) of 29.5%1. While annual digital health spending is projected to reach $660 billion by 20252.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF), (the "Company" or wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 32 countries is pleased to announce the Beta release of its new internet of medical things (IoMT) HealthHub, targeting commercial release later this year.

Based on a survey2of physicians in the United States who serve predominantly Medicare fee-for-service (FFS) and Medicare Advantage (MA) patients, McKinsey estimates that up to $265 billion (about $820 per person in the US) worth of care services - which represents up to 25% of the total cost of care - for Medicare FFS and MA beneficiaries could shift from traditional facilities to the home by 2025, without a reduction in quality or access.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Digital Health Inc. Improves Nightly Sleep by 38 Minutes for Employees Across 13 Countries Study Published in US Medical Journal

Wellteq Digital Health Inc. Improves Nightly Sleep by 38 Minutes for Employees Across 13 Countries Study Published in US Medical Journal

  • WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has deployed the Company's sleep program in partnership with WTW (NASDAQ:WTW) to improve the sleep of employees within a large financial institution with operations in over 13 countries.

  • The Wellteq sleep program resulted in an improvement in sleep duration of an average of 38 minutes per night, as published in the Journal of Community Medicine & Public Health Care in the United States1.

  • McKinseyestimates that the cost of sleep deprivation towards burnout, exhaustion and depression is $680 billion per year in just five OECD countries, in the U.S. alone, 70M people are plagued with chronic insomnia2 (McKinsey, 2021).

  • Wellteq offers its corporate and insurance customers digital solutions across the four pillars of wellbeing - activity, nutrition, mental health and sleep. These evidence-based solutions are generating health outcomesand journal publications from the sub-clinical domain as the Company advances its digital solutions toward clinical settings.

  • Digital Health is a fast-growing market with projected CAGR of 25% to reach $660 billion by 20253 (Statistica, 2021).

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) (the "Company" or Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce the publication of "The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia" in the Journal of Community Medicine & Public Health Care published in the United States. The article was co-authored by WTW (NASDAQ:WTW) Regional Senior Consultant of Workplace Health and Wellbeing, Ms. Pheona Chua.

The results were drawn from across 13 nations, 8 enterprise markets and 529 participants and demonstrate a substantial and clinically meaningful improvement in nightly sleep duration achieved by 59% of employee participants. The weighted average sleep duration increase was 38 minutes of nightly additional sleep achieved. Based on an initial average sleep duration of 7 hours, this represents a 9% increase in weighted average nightly sleep duration. To view the study, visit:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Wellteq Chairman Appointed to the Order of Canada for Leadership in Digital Health

Wellteq Chairman Appointed to the Order of Canada for Leadership in Digital Health

  • Dr. Peter W. Vaughan, CM, CD, MA, MD, MPH, ICD.D, Chairman of the Board of Directors at WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has been appointed to the Order of Canada.
  • Recognised by the Governor General of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health"
  • Digital Health market size projected at nearly 25% CAGR from 2019 to become a US$660 billion industry by 2025 (Statistica Research - July 2021)

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCBB: WTEQF), (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce the Company's Chairman, Dr Peter Vaughan, has been appointed to the Order of Canada by the Governor General of Canada.

The Governor General cited the appointment of Dr Vaughan "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
continuum global solutions

Wellteq Digital Health Inc. Upcoming Investor Events

  • WellteQ Digital Health Inc. (CSE: WTEQ / OTCQB: WTEQF) is pleased to announce two upcoming investor events.
  • Wellteq will be hosting an Investor Webcast on November 10 th , 2021.
  • Wellteq will also be participating in the 3 rd Annual Canaccord Genuity Health & Wellness Conference on November 16 th , 2021

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) , (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce two upcoming investor events.

Wellteq Investor Webcast on Wednesday, November 10th, 2021

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
CSE Bulletin: Consolidation - Komo Plant Based Foods Inc.

CSE Bulletin: Consolidation - Komo Plant Based Foods Inc.

Komo Plant Based Foods Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 9,707,102 common shares.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent Beta Thalassemia

Approval by the European Commission would expand the indications of Reblozyl for treatment of anemia in adults with beta thalassemia in Europe

In the pivotal BEYOND study, Reblozyl significantly increased hemoglobin levels, which were sustained over longer time compared to placebo

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

CHMP recommendation based on positive results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial

Sotyktu has demonstrated superior efficacy over twice-daily Otezla ® (apremilast) and placebo in improving skin clearance and symptoms

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

IVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of more than $39 million.

The new funding will be used to invest in iVexSol's Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol Myers Squibb (NYSE: BMY) today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results from TRANSCEND CLL 004 showed the study met the primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor. No new safety signals were reported for Breyanzi in this study.

"CLL is an incurable disease with complex biology and immune dysregulation that has made the development of T cell-based therapies that provide deep remission very challenging," said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. "In a population that has limited options, the TRANSCEND CLL 004 study represents the first multicenter trial evaluating a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory CLL or SLL, with results showing the potential of Breyanzi as a personalized one-time treatment approach for patients with this difficult-to-treat disease."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×